INMB Earnings & Financial Statements
INmune Bio, Inc.
$1.57
-$0.03(-1.88%)
41
Overall
60
Value
18
Tech
47
Quality
Market Cap
$44.41M
Volume
172.40K
52W Range
$1.09 - $2.60
Target Price
$7.00
INMB earnings and financial statements: INmune Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
INMB Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K |
| Operating income | -$47.38M | -$42.63M | -$29.74M | -$25.95M | -$29.15M |
| EBITDA | -$45.82M | -$42.10M | -$34.02M | -$25.95M | -$29.15M |
| Net income | -$45.90M | -$42.10M | -$30.00M | -$27.30M | -$30.34M |
| EPS (diluted) | $-1.86 | $-2.11 | $-1.67 | $-1.52 | $-1.88 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $32.35M | $39.56M | $57.00M | $81.80M | $99.94M |
| Total liabilities | $8.83M | $7.46M | $18.86M | $21.69M | $19.72M |
| Shareholders’ equity | $23.52M | $32.10M | $37.34M | $60.10M | $80.22M |
| Cash and equivalents | $24.75M | $20.92M | $35.85M | $52.15M | $74.81M |
| Long-term debt | $411.0K | $244.0K | $397.0K | $10.22M | $15.16M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$22.60M | -$33.40M | -$12.00M | -$22.69M | -$28.50M |
| Capital expenditure | -$1.04M | - | - | - | -$15.00M |
| Free cash flow | -$23.64M | -$33.40M | -$12.00M | -$22.69M | -$43.50M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | INMB | $1.57 | -1.9% | 172.40K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |